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Glioma stem-like cells constitute one of the potential origins
of gliomas, and therefore, their elimination is an essential factor
for the development of efficient therapeutic strategies. Canna-
binoids are known to exert an antitumoral action on gliomas
that relies on at least twomechanisms: induction of apoptosis of
transformed cells and inhibition of tumor angiogenesis. How-
ever, whether cannabinoids target human glioma stem cells and
their potential impact in gliomagenesis are unknown. Here, we
show that glioma stem-like cells derived fromglioblastomamul-
tiforme biopsies and the glioma cell lines U87MG andU373MG
express cannabinoid type 1 (CB1) and type 2 (CB2) receptors and
other elements of the endocannabinoid system. In gene array
experiments, CB receptor activation altered the expression of
genes involved in the regulation of stem cell proliferation and
differentiation. The cannabinoid agonists HU-210 and JWH-
133 promoted glial differentiation in a CB receptor-dependent
manner as shown by the increased number of S-100- and glial
fibrillary acidic protein-expressing cells. In parallel, cannabi-
noids decreased the cell population expressing the neuroepithe-
lial progenitormarker nestin.Moreover, cannabinoid challenge
decreased the efficiency of glioma stem-like cells to initiate gli-
oma formation in vivo, a finding that correlated with decreased
neurosphere formation and cell proliferation in secondary
xenografts. Gliomas derived from cannabinoid-treated cancer
stem-like cells were characterized with a panel of neural markers
and evidenced amoredifferentiatedphenotype anda concomitant
decrease in nestin expression. Overall, our results demonstrate
that cannabinoids target glioma stem-like cells, promote their dif-
ferentiation, and inhibit gliomagenesis, thusgiving further support
to their potential use in themanagement ofmalignant gliomas.
Malignant gliomas remain the most deadly human brain
tumors, with poor prognosis despite years of research in anti-
tumoral therapeutic strategies. A hallmark characteristic of gli-
omas is their molecular and cellular heterogeneity (1, 2), which
is considered one of the reasons for their high malignancy and
recurrence. Moreover, even morphologically or histologically
related tumors may behave very differently. Neoplastic trans-
formation of differentiated glial cells was for many years the
most accepted hypothesis to explain the origin of gliomas (1, 2).
However, recent findings support the existence of a stem cell-
derived origin for different types of cancers such as gliomas and
hematopoietic, breast, and prostate tumors (2, 3). In particular,
glioma-derived stem-like cells (GSCs)4 have been isolated from
both humanbrain tumors (4–8) and several glioma cell lines (6,
9, 10). GSCs are crucial for the malignancy of gliomas (8–10)
and may represent the consequence of transformation of the
normal neural stem cell compartment (11). These findings are
in line with the observation that gliomagenesis is frequently
associated with adult brain germinal zones, in particular the
subventricular zone (2, 3). It is therefore imperative that the
development of new therapeutic strategies for themanagement
of gliomas takes into account their cellular diversity and origin.
Among those strategies, cannabinoid-based drugs may repre-
sent an alternative to other established chemotherapeutics (12).
The discovery of an endogenous cannabinoid system (13),
together with the great improvement in our understanding of
the signaling mechanisms responsible for cannabinoid actions
(12, 13), has fostered the interest in the potential therapeutic
applications of cannabinoids (14). Several studies have demon-
strated a significant antitumoral action of cannabinoid ligands
in animal models (12). Thus, cannabinoid administration to
nude mice curbs the growth of different tumors, including gli-
omas, lung adenocarcinomas, thyroid epitheliomas, lympho-
mas, and skin carcinomas (12). The antitumoral action on gli-
omas relies on at least two mechanisms: induction of apoptosis
of tumor cells (15, 16) and inhibition of tumor angiogenesis
(17). Besides their wide distribution in tumor cells, cannabinoid
receptors are expressed and functionally active in neural pro-
genitors, in which they regulate cell proliferation and differen-
tiation (18, 19). This backgroundprompted us to investigate the
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Supplemental Material can be found at: 
actions of cannabinoids on human GSCs and their impact in
gliomagenesis. Our results show that GSCs express cannabi-
noid receptors and that cannabinoid stimulation reduces gli-
oma initiation in vivo, a finding that correlates with increased
cell differentiation. These findings provide further support for
cannabinoid-based antitumoral therapies that are able to target
the brain tumor stem cell compartment.
EXPERIMENTAL PROCEDURES
Materials—The following materials were kindly donated as
indicated: SR141716 and SR144528 (Sanofi-Aventis, Montpel-
lier, France), JWH-133 (J. Huffman), anti-mouse cannabinoid
type 1 (CB1) receptor polyclonal antibody (K. Mackie), and
anti-trimethyl-histone H3 (Lys9) polyclonal antibody (Upstate;
I. Flores). Mouse anti-human nestin monoclonal antibody and
anti-Musashi-1 polyclonal antibody were from Chemicon, and
rabbit anti-Ki-67 monoclonal antibody (clone SP6) was from
Lab Vision Corp. Anti-cannabinoid type 2 (CB2) receptor poly-
clonal antibody was from Affinity BioReagents, and anti-S-
100 antibody was from Swant. Recombinant human epider-
mal growth factor (EGF) and fibroblast growth factor 2 (FGF-2)
were fromR&D Systems.Mouse anti--tubulin III monoclonal
antibody was from Covance Inc., and anti-glial fibrillary acidic
protein (GFAP), anti-MAP2 (microtubule-associated protein
2), and anti--tubulin antibodies were from Sigma. Glioblas-
toma multiforme (World Health Organization grade IV astro-
cytoma) samples were provided by the Tissue Bank Network of
theMolecular Pathology Programof the SpanishNational Can-
cer Centre.
GSC Culture and Gliomagenesis in Vivo—GSCs were
obtained from human brain tumor biopsies digested with col-
lagenase (type Ia, Sigma) in Dulbecco’s modified Eagle’s
medium at 37 °C for 90 min (17) and grown under non-adher-
ent conditions (19) in neural stem cell culture medium com-
posed of Dulbecco’s modified Eagle’s and Ham’s F-12 media
supplemented with B-27 (Invitrogen), 50 mM Hepes, 2 g/ml
heparin, 20 ng/ml EGF, 20 ng/ml FGF-2, and 20 ng/ml leukemia
inhibitory factor. Of eight biopsies employed, five rendered
cells that fulfilled stem-like cell criteria (3). Representative
results are shown for one of these GSC lines and were also
extended to GSCs derived from classical human glioma
U87MG and U373MG cell lines. Cell lines were grown as
described (15, 17) and inoculated in vivo, and after tumor diges-
tion, GSCs were cultured. Clonal neurospheres were grown at
1000 cells/ml and analyzed by flow cytometry for the expres-
sion of different stem cell markers, including CD133, the stem
cell factor receptor c-Kit, and their ability to exclude Hoechst
33342 (side population analysis). Differentiation experiments
were performed in polyornithine-coated plates, and adherent
GSCs were grown in neural stem cell culture medium without
growth factors. GSCs were cultured in the presence of the indi-
cated stimuli after overnight growth factor deprivation.
Differentiation experiments with at least three independent
cultures were performed by quantification of the percentage of
total cells that expressed the indicated neural antigens or that
were highly positive for histone H3 trimethylated at Lys9. A
minimum of 10 fields were scored in a double-blinded manner
to minimize subjective interpretations. Quantified fields were
selected randomly by visualizing total cells with a microscope
Hoechst filter. Stock solutions of cellular effectors were pre-
pared in Me2SO, and the concentrations employed were
selected based onprevious studies on cannabinoid regulation of
neural progenitors (19). No significant influence of Me2SO on
any of the parameters determined was observed at the final
concentration used (0.1%, v/v). Control incubations included
the corresponding vehicle content. Gliomagenesis was induced
by subcutaneous flank inoculation into athymic nude mice of
U87MG-GSCs or glioblastomamultiforme (GBM)GSCs in 100
l of phosphate-buffered saline supplemented with 0.1% glu-
cose (16). In some experiments, 1.5 mg/kg JWH-133 or the
corresponding vehicle was administered daily to subcutaneous
gliomas. Tumor growth was measured with an external caliper,
and volume was calculated as (4/3)  (width/2)2 (length/2).
Fluorescence-activated Cell Sorter Analysis—GSCs were dis-
sociated with Accutase (Innovative Cell Technologies Inc., San
Diego, CA) following the manufacturer’s instructions; cells
(0.5  106/condition) were fixed in 2% paraformaldehyde at
4 °C in phosphate-buffered saline; and nonspecific binding was
blocked using 2% goat serum in phosphate-buffered saline.
Antibodies and their corresponding controls were incubated
for 30 min at 4 °C in 2% goat serum/phosphate-buffered saline,
and cells (10,000/recording) were analyzed using a FACSCali-
bur flow cytometer. Phycoerythrin-conjugated anti-CD133
(Miltenyi Biotec, Bergisch Gladbach, Germany) and phyco-
erythrin/Cy5-conjugated anti-CD117 (c-Kit; BD Biosciences)
antibodies were employed following the manufacturer’s
instructions.
mRNA Detection and Quantification—mRNA was obtained
with an RNeasy Protect kit (Qiagen Inc., Valencia, CA) using an
RNase-free DNase kit. cDNA was subsequently obtained using
a SuperScript first-strand cDNA synthesis kit (Roche Applied
Science), and amplification of cDNA was performed with the
following primers: human CB1, CGT GGG CAG CCT GTT
CCT CA (sense) and CAT GCG GGC TTG GTC TGG (anti-
sense; 403-bp product); human CB2, CGC CGG AAG CCC
TCA TAC C (sense) and CCT CAT TCG GGC CAT TCC TG
(antisense; 502-bp product); human fatty acid amide hydrolase,
TGGGAAAGGCCTGGGAAG TGAACA (sense) and GCC
GCA GAT GCC GCA GAA GGA G (antisense; 458-bp prod-
uct); human monoacylglycerol lipase, ACC CTG GGC TTC
CTG TCT TCC TTC (sense) and TTC CTG CCG TGG CTG
TCC TTT GAG (antisense; 564-bp product); human TRPV1
(transient receptor potential cation channel, subfamily V,
member 1), CGCCGCCAGCACCGAGAA (sense) and ACC
GAG TCC CTG GCG CTG ATG TC (antisense; 546-bp prod-
uct); human glyceraldehyde-3-phosphate dehydrogenase,
GGGAAGCTCACTGGCATGGCCTTCC (sense) andCAT
GTG GGC CAT GAG GTC CAC CAC (antisense; 318-bp
product); humanMusashi-1, GATGGTCAC TCGGACGAA
GAA (sense) and CAA ACC CTC TGT GCC TGT TG (anti-
sense; 149-bp product); human nestin, GAG AGG GAG GAC
AAAGTCCC (sense) andTCCCTCAGAGACTAGCGCAT
(antisense; 128-bp product); human NOTCH1, GCC GCC
TTT GTG CTT CTG TTC (sense) and CCG GTG GTC TGT
CTG GTC GTC (antisense; 251-bp product); human OCT4,
GACAACAATGAAAATCTTCAGGAGA(sense) andTTC
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TGG CGC CGG TTA CAG AAC CA (antisense; 217-bp
product); and human SOX2, GCA CAT GAA CGG CTG
GAG CAA CG (sense) and TGC TGC GAG TAG GAC ATG
CTG TAG G (antisense; 206-bp product). CB1 and CB2
receptor PCR amplifications were performed under the fol-
lowing conditions: 93 °C for 1 min; two rounds at 59 °C for
30 s, 72 °C for 1 min, and 93 °C for 30 s; two rounds at 57 °C
for 30 s, 72 °C for 1 min, and 93 °C for 30 s; and 35 cycles at
55 °C for 30 s, 72 °C for 1min, and 93 °C for 30 s. Finally, after
a final extension step at 72 °C for 5 min, PCR products were
separated on 1.5% agarose gels. Real-time quantitative PCR
was performed with TaqMan probes (Applied Biosystems,
Foster City, CA). Amplifications were run in a 7700 real-time
PCR system, and the values obtained were adjusted using 18
S RNA levels as a reference.
cDNA Arrays—Total RNA was extracted from vehicle- or
HU-210-treated GBM-GSCs cells, and poly(A) RNA was iso-
lated with Oligotex resin (Qiagen Inc.) and reverse-transcribed
with Moloney murine leukemia virus reverse transcriptase in
the presence of 50 Ci of [-33P]dATP for the generation of
radiolabeled cDNA probes. Purified radiolabeled probes were
hybridized to stem gene array membranes (GEArray Q series,
SuperArray Bioscience Corp., Frederick, MD) according to the
manufacturer’s instructions.5 Hybridization signals were
detected using a PhosphorImager and analyzed using Phoretix
housekeeping genes on the blots as internal controls for nor-
malization. The selection criteria were set conservatively
throughout the process, and the genes selectedwere required to
exhibit at least a 50% change in expression.
Western Blotting—Western blot analysis was performed as
described previously (19). Cleared cell extracts were subjected
to SDS-PAGE and transferred to polyvinylidene difluoride
membranes. Following incubation with primary antibodies,
blots were developedwith horseradish peroxidase-coupled sec-
ondary antibodies using an enhanced chemiluminescence
detection kit. Loading controls were performed with anti--
tubulin antibody. Densitometric quantification of the lumino-
grams was performed using a GS-700 imaging densitometer
(Bio-Rad) and MultiAnalyst software.
Identification of Endocannabinoids in GSCs—Samples were
dissolved in 1 volume of high pressure liquid chromatography-
grademethanol and precipitated with 1 volume of acetone, and
non-miscible material was filtered. The supernatant was evap-
orated, and the residue was partitioned between chloroform
and water. A preparative TLC plate (Silica Gel 60 F24, 1 mm)
was pre-developed with chloroform/methanol (1:1, v/v). Then,
the residue of the chloroform layer was redissolved and applied
to a Finnigan LCQ MS detector. Detection was performed
using the electrospray ionization technique with the full-scan
mass spectrometricmode, providing a full spectrum of samples
between m/z 100 and 550. The rest of the mixture was loaded
onto a TLC plate (40:6:1 (v/v) chloroform/petroleum ether/
methanol) with synthetic anandamide and 2-arachidonoylglyc-
erol as references. The plate was scrapped, and after methanol
extraction, filtrates were analyzed by gas chromatography-
mass spectrometry with an electron impact detector (Hewlett-
Packard G1800 GCD HP-5971) after derivatization with the
silylating agent N,O-bis(trimethylsilyl)trifluoroacetamide to
form trimethylsilyl ethers at free hydroxyl groups.
Immunofluorescence and Confocal Microscopy—Immuno-
fluorescence was performed in 10-m tumor sections or in
cultured cells as described previously (17, 18). Samples were
incubated with the indicated antibodies and their corre-
sponding secondary antibodies, either anti-rabbit or anti-
mouse antibody highly cross-adsorbed with Alexa Fluor 488
(Molecular Probes). CB receptor expression was determined
with anti-rabbit secondary antibody highly cross-adsorbed
with Alexa Fluor 594. The number of positive cells was nor-
malized to the total cell number identified by counterstain-
ing with TOTO-3 iodide or Hoechst 33342. GSC differenti-
ation was determined in a minimum of five tumor sections.
The human origin of the cells immunostained with the dif-
ferent neural markers was confirmed by double labeling with
anti-human nucleus antibody (Chemicon). Tumor section
CD133 staining was performed with non-conjugated anti-
body (Miltenyi Biotec) as described (7) and for in vitro cells
after 50 mM ClNH4 incubation for autofluorescence treat-
ment. Preparations were examined using Leica software and
a Leica SP2 acoustical optical beam splitter microscope with
two passes with a Kalman filter and a 1024X1024 collection
box.
Statistical Analysis—The results shown represent the
means  S.E. of the number of experiments indicated in every
case. Statistical analysis was performed by analysis of variance,
and post hoc analysis was performing using Student’s t test.
RESULTS
Glioma-derived Stem Cells Express CB Receptors—To inves-
tigate the potential effects of cannabinoids on GSCs, we first
analyzed whether these cells express CB receptors. GSCs
derived from GBM biopsies and human glioma U87MG and
U373MG cell lines were cultured and generated neurosphere
structures equivalent to those formed by normal neural stem
cells (Fig. 1A). Clonal GSC cultures were subjected to subse-
quent neurosphere passages and showed unlimited self-re-
newal ability (supplemental Fig. 1A). Thus, we characterized in
detail their stem-like cell characteristics. Immunostaining evi-
denced a high expression of the neural stem cell markers
Musashi-1 and nestin (Fig. 1A), with many cells coexpressing
both proteins (supplemental Fig. 1B). In addition, flow cytom-
etry analysis showed a CD133-positive cell population (supple-
mental Fig. 1C), the size of which depended on the tumor of
origin. The CB1 and CB2 receptors were shown by double
immunofluorescence to colocalize in nestin-positive cells both
in vitro (Fig. 1A) and in glioma xenografts (Fig. 1B); the CB1 and
CB2 receptorswere present in 49 5 and 31 7%of the nestin-
positive cells, respectively. Western blotting of GSC cultures
was also used to analyze the presence of CB receptors (Fig. 1C).
Reverse transcription PCR analysis confirmed the expression of
stemness markers, including CD133, nestin, Musashi-1, SOX2,
and NOTCH1, and the pluripotency embryonic stem cell
markerOCT4 inGSCs (Fig. 1D). These findings correlatedwith
enhanced CB receptor expression of GBM- and U87MG-GSC5 See www.superarray.com for a detailed list of the genes analyzed.
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populations compared with their respective differentiated
counterparts. In particular, GSCswere significantly enriched in
CB2 receptors at both the transcript and protein levels, in line
with the correlation between astrocytomamalignancy and CB2
receptor expression (16). Other elements of the endocannabi-
noid (eCB) signaling system were also present in GSCs, includ-
ing TRPV1 and the hydrolases monoacylglycerol lipase and
fatty acid amide hydrolase, enzymes responsible for eCB degra-
dation (Fig. 1D). Finally, GSCswere evaluated for their ability to
produce endogenous cannabinoid ligands upon incubation
with the calcium ionophore A23187
(5 M, 2 min) and subsequent iden-
tification by LCQ mass spectrome-
try (supplemental Table 1). Several
major species of 2-monoacylglycer-
ols were detected, specifically
palmitoylglycerol and stearoylglyc-
erol. In addition, 2-arachidonoyl-
glycerol and N-arachidonoylglycine,
a metabolite of anandamide, were
present in the samples at trace levels.
Gas chromatography-mass spec-
trometry analysis after derivatiza-
tion with N,O-bis(trimethylsilyl)tri-
fluoroacetamide confirmed the data
obtained by LCQ mass spectrome-
try (supplemental Table 1).
CB Receptor Activation Contrib-
utes to the Regulation of Glioma
Stem Cell Gene Expression—To
identify the potential action of can-
nabinoids on GSCs, we investigated
the changes in gene expression
induced by the synthetic cannabi-
noid agonist HU-210 (30 nM) in
GBM-GSCs. HU-210 significantly
altered the expression of 11 genes
(Fig. 2A) of the 266 genes analyzed.
Among them, seven genes involved
in regulation of the cell cycle and
cell proliferation (CDK4 (cyclin-de-
pendent kinase 4),CDKN1B (cyclin-
dependent kinase inhibitor 1B),
FGFR1 (FGF receptor 1), FGFR3
(FGF receptor-3), EGF receptor,
EGF, and integrin 4) were down-
regulated by cannabinoid stimula-
tion. In addition, the transcript lev-
els of neuronal MAP2 and the
tumor suppressorRBL1 (retinoblas-
toma-like 1) were increased. These
results were confirmed by real-time
quantitative PCR analysis of three
transcripts (Fig. 2B) and suggest
that CB receptor activation regu-
lates essential GSC functions such
as cell proliferation and differentia-
tion. However, GSC proliferation
and self-renewal were not affected by cannabinoid stimulation
during several neurosphere passages (data not shown). The
impact of CB receptor activation on differentiation-related
genes was therefore determined by quantitative PCR analysis.
HU-210 treatment increased the mRNA levels of the glia-spe-
cific markers GFAP and S-100 in a CB1 receptor-dependent
manner as evidenced by SR141716 antagonism (Fig. 3,A and B,
respectively). In addition, CB1 receptor activation resulted in
increased expression of the early neuronal marker -tubulin III
(Fig. 3C).
FIGURE 1. Glioma stem-like cells express CB receptors. A, immunofluorescence of GBM- and U87MG-
GSCs reveals the expression of Musashi-1 (Msh1) and nestin (green) together with the presence of CB1 and
CB2 receptors (red). Scale bars  40 m. B, shown is CB receptor and nestin expression in glioma
xenografts. Scale bar  20 m. C, GBM-, U87MG-, and U373MG-GSCs express human (h) CB1 and CB2
receptors as shown by Western blotting. -tub, -tubulin. D, reverse transcription PCR analysis deter-
mined the expression of transcripts for the following components of the eCB system: the CB1 and CB2
receptors, TRPV1, fatty acid amide hydrolase (FAAH), and monoacylglycerol lipase (MAGL). The indicated
stem cell-related gene transcripts were analyzed in GSCs and their differentiated counterparts. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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Cannabinoids Promote Neural Differentiation of Glioma
Stem Cells—On the basis of the results of cannabinoid regula-
tion of differentiation-related genes, we next analyzed the reg-
ulation of GBM-GSC differentiation by the CB1 andCB2 recep-
tor agonists HU-210 and JWH-133 alone or in combination
with the receptor antagonists SR141716, SR144528, and cap-
sazepine. Activation of the CB1 and CB2 receptors, as demon-
strated by the use of their respective
antagonists, decreased the nestin-
positive cell population (Fig. 4A)
and increased the more differenti-
ated cell population expressing the
glial markers GFAP and S-100
(Fig. 4, B and C, respectively) or the
neuronal marker -tubulin III (Fig.
4D). Capsazepine did not modify
the cannabinoid-induced decrease
in nestin-positive cells and the
induction of GFAP- and -tubulin
III-positive cells, although it coun-
teracted the S-100-positive cell
increase (supplemental Fig. 2). His-
tone methylation status has been
shown to correlate with changes in
neural progenitor cell differentia-
tion (20), and thus, methylation of
histone H3 at Lys9 was monitored.
HU-210 and JWH-133 increased
the number of trimethyl-histone
H3 (Lys9)-labeled cells in a CB
receptor-dependent manner as
evidenced by SR141716 and
SR144528 antagonism (Table 1).
In summary, these experiments
confirmed the neural progenitor
ability of GSC cultures that, under
differentiation conditions, attach
and recapitulate their endogenous
differentiation program. Aberrant
GSC differentiation was observed,
as previously reported (5, 6, 21).
Similarly, cannabinoids induce
both neuronal (-tubulin III) and
glial (GFAP) gene expression (Fig.
3). Many cells were observed to
coexpress both glial and neuronal
markers (supplemental Fig. 1D),
which, in the case of normal neural
stem-derived cells, segregate in
different cell compartments.
Cannabinoids Inhibit Glio-
magenesis Initiated by Glioma
Stem Cells—Stem-like cells are
considered to be the initiating cell
population of tumorigenesis.
Thus, when injected in nude mice,
U87MG- and GBM-GSCs induced
tumor formation at cell numbers
that were 30- and 10-fold lower, respectively, than their dif-
ferentiated counterparts (0.25  106 U87MG-GSCs and 1 
106 GBM-GSCs were injected to initiate tumor formation).
As cannabinoid receptor activation regulates GSCs, we
sought to determine their impact on the ability of GSCs to
initiate glioma generation in vivo. U87MG-GSCs previously
cultured in the presence of 30 nM HU-210 or JWH-133 were
FIGURE 2. Gene expression changes in cannabinoid-treated glioma stem-like cells. A, HU-210-induced
changes in GBM-GSCs were analyzed by stem gene array. Selected changes in gene expression were signifi-
cantly different (p  0.01 versus control cells). B, cannabinoid regulation of the EGF receptor (EGFR), FGFR1, and
FGFR3 transcripts was confirmed by quantitative PCR. Results correspond to three independent experiments.
**, p  0.01. C, control.
FIGURE 3. Cannabinoid regulation of glioma stem-like cell gene expression in vitro. A–C, real-time PCR
analysis of GFAP, S-100, and -tubulin III (-tubIII) expression, respectively, in GSCs treated with 30 nM HU-210,
2 M SR141716 (SR1), or both and normalized to 18 S RNA transcript levels. Results correspond to three inde-
pendent experiments. **, p  0.01 versus the control (C).
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less efficient as tumor-initiating
cells (Table 2). Moreover, canna-
binoid-treated GSCs generated
tumors with a lower growth rate,
resulting in smaller tumor size
compared with vehicle-treated
cells (Fig. 5A and Table 2). Simi-
larly, HU-210- and JWH-133-
treated GBM-GSCs were less effi-
cient in initiating gliomagenesis
(Fig. 5B and Table 2). In particular,
HU-210 notably reduced tumor
growth, whereas in the case of
JWH-133, tumors were visible
only 2 months after the rest of the
animals had been killed (Fig. 5B
and data not shown). Samples of
GSC-derived gliomas were obtained,
and their ability to form primary
spheres was determined. Tumors
generated by cannabinoid-treated
GSCs showed decreased neuro-
sphere-forming activity (Fig. 6A) and
reduced cell proliferation (Ki-67-pos-
itive cells) (Fig. 6, B and C). These
observations confirm that cannabi-
noids inhibit stem-like cell-initiated
gliomagenesis.
To analyze cannabinoid regulation
of the differentiation status of GSC-
derived tumors, progenitor markers
were analyzed by immunofluores-
cence.Tumorsderived fromcannabi-
noid-treated cells showed decreased
nestin immunoreactivity (Fig. 7A), a
finding that was also observed in glio-
mas treated in vivo with JWH-133
(54  7% relative immunoreactivity
versus 100  8% in vehicle-treated
tumors). In addition, the expression
of vimentin, a progenitormarker that
has been correlated with glioma
malignancy (22, 23), was also
decreased (48  5% relative immu-
noreactivity in JWH-133-treated tumors versus 100  9% in
vehicle-treated tumors). Next, we analyzed the expression of
differentiatedmarkers in cannabinoid-treated derived gliomas.
CB receptor activation increased the expression of the neuronal
markersMAP2 and-tubulin III (Fig. 7,B andC) and increased
S-100 glial immunoreactivity (Fig. 7D). In agreement with a
previous report (6), GFAP immunoreactivity could not be
detected, but an increase in its transcript levels was observed
(250  55% upon HU-210 treatment and 160  20% upon
JWH-133 treatment versus 100 10% upon vehicle treatment).
DISCUSSION
The recent discovery of brain cancer stem cells has impor-
tant implications both for the development of new therapeutic
FIGURE 4. Cannabinoid regulation of glioma stem-like cell differentiation in vitro. Left panels, quan-
tification of nestin-positive (A), GFAP-positive (B), S-100-positive (C), and -tubulin III (-tubIII)-positive
(D) cells (green) versus total cells. Cannabinoid-induced differentiation was analyzed after a 4-day differ-
entiation period of GBM-GSCs in the presence of vehicle (control (C)), 30 nM HU-210 alone or with 2 M
SR141716 (SR1), and 30 nM JWH-133 alone or with 2 M SR144528 (SR2). Each antagonist was also tested
alone. Results correspond to three independent experiments. *, p  0.05 versus the control; **, p  0.01.
Right panels, representative immunofluorescence images of vehicle- and cannabinoid-treated cells. Cell
nuclei are shown in blue. Scale bar  55 m.
TABLE 1
Cannabinoid regulation of histone H3 methylation
Methylation of histone H3 at Lys9 (meK9-H3) was determined in GSCs after differ-
entiation in the presence of vehicle (Control), 30 nM HU-210 alone or with 2 M
SR141716, 2 M SR141716 alone, 30 nM JWH-133 alone or with 2 M SR144528, or
2 M SR144528 alone.
meK9-H3 cells
%
Control 100  11
HU-210 188  32a
HU-210  SR141716 96  15
SR141716 98  12
JWH-133 209  35a
JWH-133  SR144528 95  16
SR144528 92  15
a p  0.01 versus the control.
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strategies for glioma management and for the evaluation of
potential pitfalls and benefits of currently available treatments
(1–3). Here, we show that GSCs express different elements of
the eCB system, including G protein-coupled receptors (CB1
and CB2), the ionotropic receptor TRPV1, and eCB-degrading
enzymes (fatty acid amide hydrolase and monoacylglycerol
lipase), and that cannabinoid agonists target the stem-like cell
compartment of brain tumors, promote GSC differentiation in
a receptor-dependent manner, and reduce gliomagenesis in
vivo. Although no overt differences between CB1 and CB2
receptor-mediated actions in GSCs
were evident in this study, potential
variations in their molecular mech-
anisms of action may occur. For
instance, it is known that the CB1
receptor (but not the CB2 receptor)
is coupled to the modulation of var-
ious Ca2 and K channels (13) and
that CB1 receptor activation is
selectively regulated by cholesterol-
enriched membrane microdomains
(24). In addition, the different
molecular species of eCBs differ in
their affinity for the two CB recep-
tor types. Thus, 2-arachidonoylg-
lycerol rather than anandamide has
been proposed as the preferential
ligand for CB2 receptors (25). Fur-
thermore, CB2 receptor-selective
enrichment in GSCs might help to
explain the observed correlation
between CB2 receptor expression
and glioma cell malignancy (16). On
the other hand, capsazepine was
able to prevent some of the cannabi-
noid actions onGSCdifferentiation,
suggesting that these ligands may
also affect TRPV1 function by as yet
unknown mechanisms. Altogether,
these observations support that the
coexpression of different CB recep-
tors in GSCs would allow these cells
not only to be pharmacologically
targeted by CB2 receptor-selective
non-psychotropic ligands (14), but
also to respond differentially
depending on the molecular com-
position of the eCB tone present in the tumor niche. Those eCB
molecules may be produced by GSCs and surrounding cells of
neuronal and glial origin (13). In this respect, altered levels of
eCBs have been reported in human GBM biopsies compared
with normal brain tissue, suggesting that this family of extracel-
lular lipid cues may be involved in the endogenous antitumoral
response (26, 27).
The malignancy of human brain tumors inversely correlates
with their degree of differentiation as shown by increased nes-
tin, Musashi-1, and doublecortin expression (28–30), whereas
FIGURE 5. Cannabinoids inhibit glioma stem cell-initiated gliomagenesis. A and B, tumor growth of
U87MG- and GBM-GSCs, respectively, treated with vehicle (control (C); F), 30 nM HU-210 (E), or JWH-133 (f)
and injected subcutaneously into immunodeficient mice. Representative images of dissected tumors are
shown below. Scale bars  0.5 (A) and 0.3 (B) cm. *, p  0.05 versus the control; **, p  0.01.
FIGURE 6. Cannabinoid inhibition of tumor-derived neurosphere formation and in vivo cell proliferation.
A, shown is the primary sphere formation from the indicated tumor biopsies. B, cell proliferation was quantified
by Ki-67 immunoreactivity in U87MG-derived (black bars) and GBM-derived (stripped bars) tumors obtained
from cannabinoid- and vehicle (control (C))-treated GSCs. **, p  0.01 versus the control. C, representative
pictures are shown for each condition. Ki-67 is shown in red, and cell nuclei are shown in green. Scale bar  90
m. Results correspond to three independent experiments.
TABLE 2
Cannabinoid regulation of glioma stem-like cell-initiated gliomagenesis
HU-210- and JWH-133-treated cells were injected subcutaneously into mice, and the efficiency of tumorigenesis (number of mice that generated tumors relative to total
injected mice and the corresponding percentages), relative tumor growth, and tumor weight at the end of the experiment were evaluated.
U87MG-GSCs GBM-GSCs
Gliomagenesis efficiency Tumor cell growth Tumor weight Gliomagenesis efficiency Tumor cell growth Tumor weight
% % g
Vehicle 6/6(100) 100  14 1.13  0.16 5/5(100) 100  17 0.43  0.08
HU-210 4/6(67) 53  4a 0.60  0.07a 3/5(60) 12  3a 0.05  0.02a
JWH-133 4/6(67) 39  6a 0.44  0.10a 3/5(60) 0a 0a
a p  0.01 versus the control.
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theirmitotic activity is inversely correlated with their increased
expression of mature glial and neuronal markers (22, 23, 31).
Thus, comparedwithGBM, low-grade astrocytomas, oligoden-
drogliomas, and neuroblastomas have a better prognosis and
much more efficient therapeutic management (1, 2). Genetic
modeling of glioma origin has shown that, in addition to differ-
entiated astrocytes (32), neural stem cells constitute a potential
niche for malignant transformation that may be more permis-
sive for malignization (11, 33). These findings were followed by
the identification of brain tumor-initiating cells through their
selective expression of CD133 (7, 8)
or their ability to exclude Hoechst
33342 (9, 10). The existence of a
brain tumor-initiating cell pheno-
type with stem cell features may
lead in the future to potential thera-
peutic strategies based on enforced
stem cell differentiation aimed at
decreasing brain tumor-initiating
ability (8, 34). In this context, a
strong correlation between poor gli-
oma prognosis and the expression
of a signature of neurogenesis-re-
lated genes has been reported
recently (23). Similarly, radial glial
progenitor cells constitute the puta-
tive origin for ependymoma (35),
and neural stem cellsmay cause cer-
ebellar tumors (34). Finally, brain
stem-like cells have been shown to
reproduce a brain tumor phenotype
in amore reliablemanner compared
with differentiated transformed
cells (36). However, it should be
kept in mind that, in addition to
much evidence supporting a role for
stem-like cells in gliomagenesis and
tumor biology (3), new studies are
required to provide definitive proof
of the concept (37). In particular, a
better understanding of the molec-
ularmechanisms responsible for the
transformation of normal neural
stem cells (38, 39) and dedifferenti-
ation of neural cells (32, 33) and of
the alternative origins of GSCs (40)
is required.
Cannabinoids are known to exert
an antitumoral action against glio-
mas (15–17), an effect that has been
extended to a variety of tumors of
different origins (12). Our new data
support that, in addition to inducing
apoptosis of differentiated trans-
formed cells (12), cannabinoids pro-
mote differentiation of GSCs and
inhibit tumor initiation. These
observations are in line with recent
findings demonstrating that cannabinoid stimulation promotes
differentiation of non-transformed adult neural progenitors
(18, 41). Moreover, the expression of CB receptors by brain
tumor-initiating cellsmay reflect their normal developmentally
regulated expression pattern by non-transformed neural stem
cells such as subventricular zone progenitors (42) and cortical
radial progenitors and hippocampal nestin type I cells (19, 41).
These findings are thus related to the link between the normal
neural stemcell compartment and tumor development (2, 3). In
conclusion, our results demonstrate the action of cannabinoids
FIGURE 7. Cannabinoid regulation of glioma stem-like cell differentiation in vivo. Left panels, quanti-
fication of nestin (A), MAP2 (B), -tubulin III (-tub III; C), and S-100 immunoreactivity (D) in HU-210- and
JWH-133-treated U87MG-GSC-derived tumors. *, p  0.05 versus the control (C); **, p  0.01. Right panels,
neural markers are shown in green, and cell nuclei are shown in red. Representative immunofluorescence
images of cannabinoid-treated tumors are shown. Results correspond to three independent experiments.
Scale bar  80 m.
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on glioma stem-like cells and thus may open new avenues for
cannabinoid-based antitumoral strategies.
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